nimacimab glp-1 news The initiation of our CBeyond™ Phase 2 trial marks exactly one year since the transformational acquisition of Bird Rock Bio and the strategic positioning of $SKYE at the forefront of metabolic health Skye Bioscience Begins Phase 2

UK prevalence is projected to double by 2040.2,3,4 Increasingly driven by obesity, diabetes, and chronic kidney disease, HF (particularly heart failure with preserved ejection fraction ) is now recognised as a systemic cardiometabolic disorder.5,6,7 Source link To view or add a comment, sign in Aldosterone synthase inhibitors are already making waves in resistant hypertension, but emerging trial data suggests they could soon find a role in heart failure and chronic kidney disease

Having a solid side effect management plan and realistic expectations about temporary discomfort separates those who succeed from those who quit

Safety and Simplicity: Lets be practical

American Society of Anesthesiologists Chen YH, et al

Mongraw-Chaffin ML, Anderson CA, Allison MA, Ouyang P, Szklo M, Vaidya D, Woodward M, Golden SH